|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mechanism and efficacy of PARP inhibitors have been well studied in some cancers, especially homologous recombination (HR)-deficient ovarian cancer and breast cancer, yet such studies are still relatively fewer in lung cancer.
|
31753490 |
2020 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated associations between the risk of lung cancer in residents of the coal-mining region and polymorphisms in the genes APEX1 (rs1130409), hOGG1 (rs1052133), XRCC1 (rs25489, rs25487), XRCC2 (rs3218536), XRCC3 (rs861539), ADPRT/PARP1 (rs1136410), XPD/ERCC2 (rs13181), XPG/ERCC5 (rs17655), XPC (rs2228001), ATM (rs1801516), and NBS1 (rs1805794).
|
31584889 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
|
31216465 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to evaluate the inhibitory effect of AMF against PARP-1 and its potentiation on CBP in lung cancer both in vitro and in vivo.
|
30466996 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
|
29453076 |
2018 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several PARP-1 positron emission tomography (PET) imaging agents have been developed and show promise for imaging PARP-1 expression in breast, brain, and lung cancer in small animals, but not as yet in prostate cancer.
|
30195072 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that protein catabolism, proteolytic markers, muscle fiber phenotype, and muscle anabolism may improve in respiratory and limb muscles of LC-cachectic Parp-1-deficient (Parp-1<sup>-/-</sup> ) and Parp-2<sup>-/-</sup> mice.
|
28177129 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of TGF-β-induced cisplatin resistance in A549 cell through blocking the cisplatin-induced apoptosis and cell death, which characterized as the increasing of cell viability and decreasing of PARP and caspase3 cleavage in the cisplatin-treated cell.
|
28848138 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings support the view that PARP-1 Val762Ala polymorphism may contribute to an increased risk of lung cancer in the Chinese population, especially for adenocarcinoma.
|
25179837 |
2015 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, miR-224 attenuated TNF-α induced apoptosis by direct targeting of CASP3 resulting in reduction of cleaved PARP1 expression in lung cancer cells.
|
26307684 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
IC50 values measured by sulforhodamine B (SRB) assay at 72 h and apoptosis assays (annexin V staining, cleavage of PARP and caspase-3) suggest that FLLL12 is 5-10-fold more potent than curcumin against a panel of premalignant and malignant lung cancer cell lines, depending on the cell line.
|
25917567 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulated expression of DNA repair proteins, such as PARP, has been studied in lung cancer as a possible biomarker and clinically useful target, but the literature remains relatively poor.
|
24191958 |
2014 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study found that PARP-1 rs3219073 C>G polymorphism is indeed associated with lung cancer susceptibility.
|
25225750 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will focus on the possible applications of H2AX as a key regulator of DNA damage response in lung cancer and as a biomarker of: sensitivity of lung tumors to chemotherapy and radiotherapy, treatment with PARP inhibitors, bystander effect, multistep lung carcinogenesis, environmental smoking, and chemical genotoxicity, chemoprevention, prognosis, and also as therapeutic targets in lung cancers.
|
24164298 |
2013 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.
|
23275151 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings provide insight into the mechanisms of cisplatin and PARP inhibitor sensitivity of EGFR-mutant cells, yielding potential therapeutic opportunities for further treatment individualization in this genetically defined subset of lung cancer.
|
23966292 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examines the association between 24 single-nucleotide polymorphisms (SNPs) belonging to five BER genes (XRCC1, APEX1, PARP1, MUTYH and OGG1) and lung cancer among Latinos (113 cases and 299 controls) and African-Americans (255 cases and 280 controls).
|
19029194 |
2009 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that vimentin expression in lung cancer cells is regulated at the transcriptional level and that PARP-1 binds and activates the vimentin promoter independent of its catalytic domain and may play a role in H(2)O(2)-induced inhibition of vimentin expression.
|
17720873 |
2007 |